A detailed history of Bridgeway Capital Management, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 235,600 shares of DSGN stock, worth $1.47 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
235,600
Previous 235,600 -0.0%
Holding current value
$1.47 Million
Previous $789,000 60.58%
% of portfolio
0.03%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.23 - $4.77 $289,731 - $427,868
89,700 Added 61.48%
235,600 $789,000
Q4 2023

Feb 14, 2024

BUY
$1.99 - $2.76 $130,146 - $180,504
65,400 Added 81.24%
145,900 $386,000
Q3 2023

Nov 14, 2023

BUY
$2.05 - $8.14 $165,025 - $655,270
80,500 New
80,500 $189,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.